Regulatory

Travere Therapeutics gains FDA approval for sparsentan in FSGS

Pharmaceutical Business Review

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.

Regulatory Rare Disease Read full story

pharminent April 14, 2026 (Last updated: April 14, 2026)

Pharmaceutical Business Review

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition.

Regulatory Rare Disease Read full story

Related Stories

Lilly wins new FDA approval for eczema drug Ebglyss

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

Bayer’s asundexian starts EU review for ischaemic stroke

You May Have Missed

Aquipta recommended by NICE for acute migraine treatment

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Lilly wins new FDA approval for eczema drug Ebglyss

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug